Objective To investigate the clinical efficacy and safety of two chemotherapy regimens based on oxaliplatin combined with TS-1 or capecitabine in the treatment of advanced colon cancer.Methods 53 advanced colon cancer patients were involved in this study.26 patients were given the regimen of SOX:oxaliplatin (130 mg/m2) was administered intravenously in three hours on day 1,while S-1 (40 mg/m2) was administered orally twice daily for 14 consecutive days.27 patients were given the regimen of XELOX:oxaliplatin capecitabine was administered intravenously in three hours on day 1,while capecitabine (1000 mg/m2)was administered orally twice daily for 14 consecutive days.The regimens were repeated every 3 weeks.The efficacy and toxicy were evaluated after 2 cycles teatment.Results All the 53 patients were eligible for enrollment and the patients were appreciable for efficacy and toxicy.The objective response rates (RR) were 46.1％ (12/26) and 48.1％ (13/27) in the SOX group and XELOX group respectively.The disease control rates (DCR) were 76.9 ％ (20/26) and 74.1％ (20/27).There was no significant difference in RR.The objective side effects associated with the two regimens were bone marrow suppressive,digestive system reaction (diarrhea or vomiting),peripheral neuropathy and hand-foot syndrome on mostly graded 1 or 2.Compared to the XELOX group,nausea vomiting of the SOX group were higher (x2 =4.462,P =0.035),but diarrhea and hand-foot syndrome of XELOX group was obviously higher than that of SOX group [44.4 ％ (12/27) vs.19.2 ％ (5/26) (x2 =4.366,P =0.001),44.4 ％ (12/27) vs.3.8 ％ (1/26) (x2 =11.699,P=0.037)].Conclusion There are no significant difference in the efficacy of the two chemotherapy regimens and the side toxicities are all well tolerable.